Key facts
- This page summarizes Lisa Rojkjaer's Form 4 filing for Viracta Therapeutics, Inc. (VIRX).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 28 Feb 2023, 17:28.
Lisa Rojkjaer - 25 Feb 2023 Form 4 Insider Report for Viracta Therapeutics, Inc. (VIRX)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- VIRX
- Reported as of
- 25 Feb 2023
- Net transaction value
- -$3,625
- SEC form
- 4
- Accepted by SEC
- 28 Feb 2023, 17:28:28 UTC
- Prior SEC filing
- 29 Nov 2022
- Next SEC filing
- 17 Mar 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Daniel Chevallard, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Lisa Rojkjaer filed Form 4 for Viracta Therapeutics, Inc. (VIRX) on 28 Feb 2023.
Change
- Previous filing in this sequence was filed on 29 Nov 2022.
- Current net transaction value: -$3,625.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VIRX
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +4,127
- Change %
- +8.9%
- Price
- $0.000000
- Shares after
- 50,243
- Date
- 25 Feb 2023
- Ownership
- Direct
- Footnotes
- F1
VIRX
transaction
Common Stock
Sale
- Transaction value
- $3,625
- Shares
- -2,156
- Change %
- -4.3%
- Price
- $1.68
- Shares after
- 48,087
- Date
- 27 Feb 2023
- Ownership
- Direct
- Footnotes
- F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VIRX
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -4,127
- Change %
- -10%
- Price
- $0.000000
- Shares after
- 37,146
- Date
- 25 Feb 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,127
- Exercise price
- Footnotes
- F1, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.
Footnote F2
The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the reporting person's award agreement to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction.
Footnote F3
Represents the weighted average share price of an aggregate total of 2,116 shares sold in the price range of $1.68 to $1.72 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Footnote F4
One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.